Source: Registered Drug Product Database (NG) Revision Year: 2022 Publisher: Exphar s.a., Zoning Industriel de Nivelles Sud, zone II, Av. Thomas Edison 105, 1402 Thines (Belgium), Phone +32 (0)67 68 84 05, Fax +32 (0)67 68 84 19 Manufacturer: Gracure Pharmaceuticals Ltd., E-1105, RIICO Industrial Area, Phase-III, Bhiwadi, Dist. Alwar (Raj.) INDIA, Phone: +91 1493 221316, Fax: +91 1493 220659
ANTALGEX T is indicated for the symptomatic treatment of moderate to severe pain. The use of ANTALGEX T should be restricted to patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol (see section 5.1).
The use of ANTALGEX T should be restricted to patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol.
The dose should be individually adjusted according to the intensity of the pain and to the sensibility of the patient. In general, the lowest dose producing analgesic effect should be selected.
A total daily dose of 8 capsules (equivalent to 300 mg of tramadol and 2600 mg of paracetamol) should not be exceeded. The dosing interval should not be less than 6 hours.
An initial dose of two capsules of ANTALGEX T is recommended. Additional doses can be taken as needed, not exceeding 8 capsules (equivalent to 300 mg of tramadol and 2600 mg of paracetamol) per day.
The dosing interval should not be less than 6 hours.
ANTALGEX T should under no circumstances be administered for longer than it is strictly necessary (see also section 4.4 Special warnings and precautions for use). If repeated use or long term treatment with ANTALGEX T is required as a result of the nature and severity of the illness, then a careful, regular monitoring should take place (with breaks in the treatment, where possible), to assess whether the continuation of the treatment is necessary.
The effective and safe use of ANTALGEX T has not been established in children below the age of 12 years old. The treatment is therefore not recommended in this population.
A dosing adjustment is generally not required in patients aged 75 years old or less without clinically manifest hepatic or renal insufficiency. In patients over 75 years old, the elimination may be extended. Then, if required, the dosing interval should be prolonged in terms of the patient’s needs.
The elimination of tramadol is delayed in patients with renal insufficiency. In those patients, a prolongation of the dosing intervals should be considered carefully in terms of the patient’s needs.
In patients with hepatic impairment the elimination of tramadol is delayed. In these patients, prolongation of the dosage intervals should be carefully considered according to patient’s requirements (see section 4.4). Because of the presence of paracetamol, ANTALGEX T should not be used in patients with severe hepatic impairment (see section 4.3).
Oral use.
Capsules should be swallowed whole, with a sufficient amount of beverage.
ANTALGEX T is a fixed combination of active substances. In case of an overdose, the symptoms may include the signs and symptoms of toxicity of tramadol or paracetamol or both of these active ingredients.
In principle, when intoxicated with tramadol, symptoms similar to those of other centrally acting analgesics (opioids) are to be expected. These include mostly, miosis, vomiting, cardiovascular collapse, consciousness disorders that can lead to coma, convulsions and respiratory depression up to respiratory arrest. Serotonin syndrome also has been reported.
An overdose is of particular concern in young children.
Symptoms of paracetamol overdose in the first 24 hours are the following: pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage.
Cardiac arrhythmias and pancreatitis have been reported.
Liver damage is possible in adults who have taken 7.5-10 g or more of paracetamol. It is considered that excess quantities of a toxic metabolite (usually adequately detoxified by glutathione when normal doses of paracetamol are ingested) could become irreversibly bounded to liver tissue.
Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Any adult or adolescent who had ingested around 7.5 g or more of paracetamol in the preceding 4 hours or any child who has ingested ≥150 mg/kg of paracetamol in the preceding 4 hours should undergo gastric lavage.
Paracetamol plasmatic concentrations should be measured later than 4 hours after overdose in order to be able to assess the risk of developing liver damage (via the paracetamol overdose nomogram). Administration of oral methionine or intravenous N-acetylcysteine (NAC) which may have a beneficial effect up to at least 48 hours after the overdose, may be required. Administration of intravenous NAC is most beneficial when initiated within 8 hours of overdose ingestion. However, NAC should still be given if the time to presentation is greater than 8 hours after overdose and continued for a full course of therapy. NAC treatment should be started immediately when massive overdose is suspected. General life supportive measures must be put in place.
Irrespective of the reported quantity of paracetamol ingested, the antidote for paracetamol, NAC, should be administered orally or intravenously, as quickly as possible, if possible, within 8 hours following the overdose.
3 years.
Store in the original package, protect from heat, light and moisture.
Store below 30°C.
ANTALGEX T is available in boxes of 20 capsules.
ANTALGEX T capsules are packed in PVC/Aluminium blisters.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.